Sunitinib: Preliminary Phase II data

Preliminary data from a Phase II trial in 12 evaluable patients with advanced NSCLC showed that 37.5 mg/day of sunitinib plus 150 mg/day of erlotinib produced 2 partial responses and 2 cases of stable...